Sign up
Pharma Capital

Drug developer Motif Bio's antibiotic successfully completes first phase III trial

The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections
bacteria.jpg
The company are waiting for the results of second trial before filing a new drug application

Motif Bio Plc (LON: MTFB, NASDAQ:MTFB) chief executive Graham Lumsden hailed as a “significant achievement” the successful completion of a phase III clinical trial of its next-generation antibiotic, iclaprim.

The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections (ABSSSI).

WATCH: Motif boss: "All good news" ... 

SIGN-UP: Click to receive the Proactive newsletter

The top-line results revealed it scored well against one of the leading products, vancomycin, on two counts.

Researchers were assessing whether iclaprim was ‘non-inferior’ to vancomycin in the 48 to 72 hours after the start of administration and at the test of cure, a week to a fortnight after patients stop receiving treatment. It also did well in meeting several secondary ‘endpoints’, investors were told.

Kidney disease boost

Data from REVIVE-2, the second phase III trial, which uses an identical protocol but has different trial centres, are expected in the second half of the year.

Motif plans to make a new drug application in the first half of 2018.

It is thought iclaprim could be an important treatment for patients with ABSSSI who may have kidney disease – which is around a quarter of the 3.6mln annually that catch the infection.

"The successful completion of REVIVE-1 is a significant achievement for Motif Bio. I would like to thank the patients and physicians that participated in this important study,” said CEO Lumsden.

Ian_55ae0ddd437b7.jpg
Why Invest In Motif Bio Plc? Read More Here

Register here to be notified of future MTFB Company articles
View full MTFB profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.